CUMBERLAND PHARMACEUTICALS INC
CPIXNasdaqHealthcare · Pharmaceutical Preparations · TN · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $11.7M | $8.5M | $9.2M | $11.2M | $35.0M | $35.8M |
| Operating income | $1.3M | −$1.9M | −$1.5M | −$1.3M | −$324,300 | −$1.8M |
| Net income | $1.3M | −$1.9M | $192,184 | −$1.4M | $166,828 | −$1.1M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M | $96.5M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M | $49.6M |
| Equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M | $47.0M |
| EPS (diluted) | $0.08 | $-0.14 | $-0.44 | $-0.38 | $0.01 | $-0.07 |
| Shares out. | 14.0M | 14.2M | 14.4M | 14.8M | 14.9M | 15.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 11.0%
- Net margin
- 10.7%
- Return on equity
- 5.1%
- Return on assets
- 1.6%
- Return on capital (ROCE)
- 3.2%
- Liabilities / assets
- 68.1%
- Debt / equity
- 2.10×
- Book value / share
- $1.78
- Revenue growth (YoY)
- 37.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.50distress
- Accruals / assets
- −4.8%clean
- Beneish M-Score
- -2.52normal
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 good- Altman Z″ in the distress zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- OMECLAMOX-PAKFeb 8, 2011
- VIBATIVSep 11, 2009
- SANCUSOSep 12, 2008
- VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINERDec 29, 2005
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-06Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
- Phase 2Recruitingreadout ~2027-01Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Kazimi A JPassive (13G)Feb 9, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Oct 30, 2025
- Ikarian Capital, LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Brown Martin S JrDirector | Mar 18, 2026 | Grant | 1,800 | $2.80 |
| Galante Joseph CDirector | Mar 18, 2026 | Grant | 1,800 | $2.80 |
| Jones JamesDirector | Mar 18, 2026 | Grant | 1,800 | $2.80 |
| Krogulski KennethDirector | Mar 18, 2026 | Grant | 1,800 | $2.80 |
| Young CarolineDirector | Mar 18, 2026 | Grant | 1,800 | $2.80 |
| Kazimi A JOfficer — Chairman and CEO | Mar 16, 2026 | Tax withholding | 5,845 | $3.06 |
| Young CarolineDirector | Dec 1, 2025 | L | 4 | $2.36 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 454,750 | 2.5 | -13.1% |
| Apr 30, 2026 | 523,399 | 1.0 | +363.6% |
| Apr 15, 2026 | 112,896 | 2.6 | +2.9% |
| Mar 31, 2026 | 109,732 | 1.9 | -23.1% |
| Mar 13, 2026 | 142,752 | 1.0 | -21.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Shareholder voteApr 24, 2026
- Entered a material agreement · Regulation FD disclosure · Other material eventApr 23, 2026
- Results of operationsMar 3, 2026
- Other material eventFeb 4, 2026
- Entered a material agreement · New financial obligationNov 24, 2025
- Results of operationsNov 4, 2025
- Other material eventOct 21, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.